Physician profile
Emily Weng
NPI 1003311143
$6,799.67
in general payments reported to CMS, 2019-2025
26 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $423 · 2022: $960 · 2023: $1,266 · 2024: $1,856 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Travel and Lodging: $1,960 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.92 |
| Travel and Lodging | $1,959.60 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,700.88 | 2021-2025 | Orise, Spyglass, Dreamtome Rx 49 |
| Gilead Sciences, INC. | $1,207.41 | 2021-2025 | Livdelzi, Vemlidy |
| Abbvie INC. | $918.80 | 2021-2025 | Skyrizi |
| Janssen Biotech, INC. | $410.75 | 2023-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $217.19 | 2024-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $210.55 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $136.46 | 2022 | |
| Mallinckrodt Hospital Products INC. | $127.75 | 2022-2025 | Terlivaz |
| Janssen Scientific Affairs, LLC | $117.34 | 2023 | Stelara |
| Ardelyx, INC. | $110.96 | 2023-2025 | Ibsrela |
| Dynavax Technologies Corporation | $100.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $94.56 | 2023-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.80 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $54.07 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Madrigal Pharmaceuticals | $45.35 | 2025 | Rezdiffra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vibrant Gastro, INC. | $42.68 | 2024 | Vibrant Starter Kit |
| Phathom Pharmaceuticals, INC. | $32.49 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $30.85 | 2025 | Cologuard Collection Kit |
| Celltrion USA INC. | $24.21 | 2025 | Vegzelma |
| Celgene Corporation | $21.64 | 2024 | Zeposia |
| Qol Medical, LLC | $19.80 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $19.76 | 2024 | |
| Aimmune Therapeutics, INC. | $18.85 | 2025 | Zenpep |
| Erbe USA INC | $17.68 | 2024 | |
| Braintree Laboratories, INC. | $15.61 | 2025 | Sutab |
| Evoke Pharma, INC. | $14.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Weng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.